7th Annual Private Equity U.S. Forum

Markets Group

Speaking Engagement | May.09.2018 - May.10.2018

Harmonie Club

Partner Pete Lamb will be a panelist in the at the 7th Annual Private Equity U.S. Forum on the panel "Middle Market & Growth Investing" on Wednesday, May 9 at 3:45 p.m.

This panel will discuss how in this crowded private market, how high valuations are slowing the investment pace, GPs have been forced to be more creative in finding value. Increasingly, in the middle market more firms are seeking growth equity investment opportunities rather than traditional leveraged buyouts. Hybrid, crossover and growth funds are on the rise. How are investors sourcing deals for non-control investments? What challenges and opportunities lie ahead in the realm of growth in-vesting for managers and institutional investors?

For more information about the conference, or to register, click below.

CLE Credits Available: N

17097_740x360

Practice:

  • Corporate
  • M&A and Private Equity
  • Capital Markets
  • Corporate Governance
  • Technology Companies Group
  • Fintech

Peter M. Lamb Partner Corporate, M&A and Private Equity

Silicon Valley; Portland

Peter Lamb, a partner working across our Bay Area and Pacific Northwest offices, is a member of the Corporate Group. Peter advises private equity sponsors, technology investors, and well established private and public technology and life sciences companies.

Peter advises private equity funds and their portfolio companies on M&A and minority and majority investments. He also advises a range of mid- to late-stage private technology companies, including Aptean, Duetto Research, ESS, ProCare, Qualifacts, Sagent Lending Solutions, Stripe, Trax Retail and Zimperium. Peter regularly works with Warburg Pincus on a wide range of technology, healthcare IT and life sciences platform investments and portfolio company transactions.

Peter has also advised on the IPOs and follow-ons of numerous companies, including Cortexyme, Twist Bioscience, Elevate Financial, AVG Technologies, Pandora Media, Chegg, Portola Pharmaceuticals and ZS Pharma. His experience includes a wide range of public and private company M&A, growth equity and public market financings for tech, life sciences and private equity clients, as well as numerous cross-border buy- and sell-side M&A representations, including the $1.3 billion sale of AVG Technologies to Avast Software, and a dozen roll-up acquisitions for TA Associates and Vista Equity-backed Aptean.